Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
  • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
  • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Definitions

• the present invention relates to novel compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
• Phosphodiesterase type 10A (hereinafter PDEIOA) is a dual- substrate
• PDEIOA phosphodiesterase that can convert both cAMP to AMP and cGMP to GMP.
• PDEIOA is highly prominent in the mammalian brain. In the rat, as well as in other mammalian species, PDEIOA and the mRNA of PDEIOA are highly enriched in the GABAergic medium spiny projection neurons (MSNs) of the striatal complex (caudate nucleus, nucleus accumbens, and olfactory tubercle) where the output is regulated by the effect of PDEIOA on cAMP and cGMP signalling cascades (see e.g. C. J. Schmidt et al, The Journal of Pharmacology and Experimental Therapeutics 325 (2008) 681-690, A. Nishi, The Journal of Neuroscience 2008, 28, 10450-10471).
• MSNs GABAergic medium spiny projection neurons
• MSNs express two functional classes of neurons: the Di class expressing Di dopamine receptors and the D 2 class expressing D 2 dopamine receptors.
• the Di class of neurons is part of the 'direct' striatal output pathway, which broadly functions to facilitate behavioral responses.
• the D 2 class of neurons is part of the 'indirect' striatal output pathway, which functions to suppress behavioral responses that compete with those being facilitated by the 'direct' pathway.
• PDEIOA regulation of cAMP and/or cGMP signaling in the dendritic compartment of these neurons may be involved in filtering the cortico/thalamic input into the MSN.
• PDEIOA may be involved in the regulation of GAB A release in the substantia nigra and globus pallidus (Seeger, T.F. et al. Brain Research, 2003, 985, 1 13-126). Inhibition of PDEIOA results in striatal activation and behavioral suppression such as dampened locomotion, inhibition of conditioned avoidance response (CAR), and activity in the rat auditory gating model, suggesting that inhibitors of phosphodiesterase type 10A represent a novel class of antipsychotic agents.
• CAR conditioned avoidance response
• Papaverine potentiated the cataleptic effect of the D 2 receptor antagonist haloperidol in rats, but did not cause catalepsy on its own (WO 03/093499).
• Papaverine reduced hyperactivity in rats induced by PCP, while reduction of amphetamine-induced hyperactivity was insignificant (WO 03/093499).
• PDEIOA inhibition has the classic antipsychotic potential that would be expected from theoretical considerations.
• Papaverine however has significant limitations in this regard with relatively poor potency and selectivity and a very short exposure half- life after systemic administration. It was found that inhibition of PDEIOA reverses subchronic PCP-induced deficits in attentional set-shifting in rats suggesting that PDEIOA inhibitors might alleviate cognitive deficits associated with schizophrenia. (Rodefer et al, Eur. J. Neurosci., 4 (2005) 1070-1076).
• the new class of inhibitors are exemplified by MP-10 (PF-2545920: 2- ⁇ 4-[l- methylpyridine-4-yl-l-H-pyrazol-3-31y]phenoxymethyl ⁇ -quinoline) and TP- 10, i.e. 2- ⁇ 4-[pyridine-4-yl- 1 -(2,2,2-trifluoroethyl)- 1 -H-pyrazol-3-31y]phenoxymethyl ⁇ - quinoline.
• the compounds offer a therapeutic approach to the treatment of
• Positive signals in rodent models of schizophrenia include the: attenuation of conditioned avoidance response (CAR), inhibition of hyperactivity caused by amphetamine-induced dopamine release or phencyclidine (PCP) mediated NMDA receptor blockade, attenuation of pharmacologically impaired social or object recognition, and antagonism of apomorphine-induced climbing.
• CAR conditioned avoidance response
• PCP phencyclidine
• PDE10 inhibitiors may have the potential for the treatment of Huntington ' s disease (S. H. Francis et al., Physiol. Rev., 91 (2011) 651- 690) and they may be a therapeutic option for substance abuse disorders (F. Sotty et al, J. Neurochem., 109 (2009) 766-775). Furthermore, it has been suggested that PDEIOA inhibitors may be useful for treatment of obesity and non- insulin dependent diabetes (see e.g. WO 2005/120514, WO 2005/012485, Cantin et al, Bioorganic & Medicinal Chemistry Letters 17 (2007) 2869-2873).
• inhibitors of PDEIOA offer a promising therapeutic approach to the treatment or prevention of neurological and psychiatric disorders, in particular schizophrenia and related disorders, including symptoms linked to schizophrenia such as cognitive dysfunction.
• MP10 and MP10 like componds US 2007/0155779, WO 2008/001182 and WO 2008/004117; and
• metabolic stability in particular microsomal stability, e.g. measured in vitro, in liver microsomes from various species (e.g. rat or human) in human cells, such as hepatocytes;
• cytochrome P450 is the name for a superfamily of heme proteins having enzymatic activity (oxidase). They are also particularly important for the degradation (metabolism) of foreign substances such as drugs or xenobiotics in mammalian organisms.
• the principal representatives of the types and subtypes of CYP in the human body are: CYP 1A2, CYP 2C9, CYP 2D6 and CYP 3A4. If CYP 3A4 inhibitors (e.g.
• grapefruit juice, cimetidine, erythromycin are used at the same time as medicinal substances which are degraded by this enzyme system and thus compete for the same binding site on the enzyme, the degradation thereof may be slowed down and thus effects and side effects of the administered medicinal substance may be undesirably enhanced;
• the pharmacokinetics can be described by the following parameters: half-life, volume of distribution (in l'kg “1 ), plasma clearance (in l-h "1 'kg '1 ), AUC
• IC50 in this dofetilide assay means a greater probability of potent hERG blockade.
• the blockade of the hERG channel can be measured by electrophysiological experiments on cells which have been transfected with the hERG channel, by so-called whole-cell patch clamping (G. J. Diaz et al., Journal of Pharmacological and Toxico logical Methods, 50 (2004), 187-199).
• the present invention is thus based on the object of providing compounds which inhibit PDE10A at low concentrations.
• the compounds are further intended to display at least one of the properties i. to viii. mentioned above, in particular high selectivity with regard to inhibition of
• PDE10A high selectivity vis-a-vis other phosphodiesterases such as , enhanced metabolic stability, in particular microsomal and/or cytosolic stability, low affinity to the HERG receptor, low inhibition of cytochrome P450 (CYP) enzymes, suitable solubility in water and suitable pharmacokinetics.
• CYP cytochrome P450
• -X 5 C(R 9 )-, where X 5 is bound to the carbon atom which carries R 2 ; is N or C-R 9 ;
• phenyl which carries a monocyclic hetaryl radical having 1 or 2 nitrogen atoms and optionally a further heteroatom selected from O, S and N as ring members, which in addition to monocyclic hetaryl, may carry 1, 2 or 3 identical or different substituents R x ,
• R x is selected from the group consisting of H, halogen, Ci-C 4 -alkyl, Ci-C 4 -alkoxy, Ci-C 4 -fluoroalkyl, Ci-C 4 -fluoroalkoxy, C 3 -C 6 - cycloalkyl, Ci-C 4 -alkoxy-Ci-C 4 -alkoxy, Ci-C 4 -alkoxy-Ci-C 4 - alkyl, OH, hydroxy-Ci-C 4 -alkyl, 0-C 3 -C 6 -cycloalkyl, benzyloxy, C(0)0-(Ci-C 4 -alkyl), 0-(Ci-C 4 -alkyl)-C0 2 H, N(R xl )(R x2 ), C(0)N(R xl )(R x2 ), Ci-C 4 -alkyl-N(R xl )(R x2 ), Ci-C
• R xl , R x2 , R x3 and R x4 independently of each other are selected from the group consisting of hydrogen, Ci-C 4 -alkyl, Ci-C 4 -fluoroalkyl and C3-C6-cycloalkyl or R xl and R x2 form together with the N atom to which they are attached a 3- to 7-membered, nitrogen heterocycle which may have 1 , 2 or 3 further different or identical heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and S0 2 as ring members and which may carry 1 , 2, 3, 4, 5 or 6 substituents selected from Ci-C 4 -alkyl,
• R x which are bound at adjacent carbon atoms may form a fused 5- or 6-membered saturated carbocyclic radical or a fused 5- or 6-membered heterocyclic radical having 1 , 2 or 3 heteroatoms as ring members, which are selected from O, S and N; is selected from the group consisting of hydrogen, halogen, OH, Ci- C 4 -alkyl, trimethylsilyl, Ci-C 4 -alkylsulfanyl, Ci-C 4 -alkoxy-Ci-C 4 - alkyl, Ci-C 4 -alkoxy, Ci-C 4 -alkoxy-Ci-C 4 -alkoxy, Ci-C 4 -alkylsulfanyl- Ci-C 4 -alkoxy, C 2 -C 4 -alkenyloxy, Ci-C 4 -fluoroalkyl, Ci-C 4 - fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2
• R 3 , R 4 , R 5 , R 6 independently of each other are selected from the group consisting of hydrogen, halogen, Ci-C 4 -alkyl, trimethylsilyl, Ci-C 4 -fluoroalkyl, Ci-C 4 -fluoroalkoxy, C3-C6-cycloalkyl, or the radicals together with the carbon atoms to which they are bound form a saturated 3- to 6- membered carbocycle or a saturated 3- to 6-membered heterocycle having 1 or 2 non-adjacent heteroatoms as ring members, where the carbocycle and the heterocycle are unsubstituted or may carry 1, 2, 3 or 4 substituents selected from fluorine and methyl or either the radicals R 3 , R 4 or the radicals R 5 , R 6 together with the carbon atom to which they are bound form a saturated 3- to 6-membered carbocycle or a saturated 3- to 6-membered heterocycle having 1 or 2 non- adjacent heteroatoms as ring members, where the
• a * is a O, NR 3a , CR 3b R 3c or linear C 2 -C 3 -alkandiyl, where one of the
• CH 2 -moieties of C 2 -C 3 -alkandiyl may be replaced by oxygen or NR 3a , and where 1, 2, 3, or 4 of the hydrogen atoms of C 2 -C 3 -alkandiyl may be replaced by a radical R 3d , where
• R 3a is hydrogen or Ci-C4-alkyl
• R 3b , R 3c independently of each other are selected from the group consisting of hydrogen, halogen, Ci-C4-alkyl or R 3b and R 3c together form C 2 -C3-alkandiyl;
• R 3d is selected from the group consisting of halogen and C 1 -C4- alkyl; independently of each other are selected from the group consisting of hydrogen and Ci-C4-alkyl; is selected from the group consisting of hydrogen, halogen, OH, Ci- C 4 -alkyl, trimethylsilyl, Ci-C 4 -alkylsulfanyl, Ci-C 4 -alkoxy-Ci-C 4 - alkyl, Ci-C 4 -alkoxy, Ci-C 4 -alkoxy-Ci-C 4 -alkoxy, Ci-C 4 -alkylsulfanyl- Ci-C 4 -alkoxy, C 2 -C 4 -alkenyloxy, Ci-C 4 -fluoroalkyl, C 1 -C 4 - fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, fluorinated cyclopropyl, CN, NR x
• Cyc 1 , Cyc 2 , Cyc 3 independently of each other are selected from the group
• phenyl, naphthyl, the saturated or partially unsaturated heteromonocyclic and heterobicyclic radicals and the mono and bicyclic heteroaromatic radicals are unsubstituted or carry 1, 2, 3, 4 or
• R C1 is selected from hydrogen, halogen, OH, CN, N0 2 , Ci-C 4 -alkyl, Ci-C 4 -alkoxy, Ci-C 4 -alkylsulfanyl, hydroxy-Ci-C 4 -alkyl, C 1 -C 4 - alkoxy-Ci-C 4 -alkyl, Ci-C 4 -alkoxy-Ci-C 4 -alkoxy, cyano-Ci-C 4 - alkyl, Ci-C 4 -fluoroalkyl, Ci-C 4 -fluoroalkoxy, C 1 -C 4 - alkylsulfonyl, C(0)R a , Z-C(0)OR b , Z-C(0)NR c R d , S(0) 2 NR c R d and Z-NR e R f , where
• R a is selected from the group consisting of Ci-C 4 -alkyl and Ci-C 4 -fluoroalkyl
• R b is selected from the group consisting of hydrogen, C 1 -C 4 - alkyl, C 2 -C4-alkenyl and Ci-C 4 -fluoroalkyl
• R c , R d is selected from the group consisting of hydrogen, C 1 -C4- alkyl, Ci-C 4 -fluoroalkyl, Ci-C 4 -alkoxy and C 1 -C 4 - fluoroalkoxy,
• R e , R f is selected from the group consisting of hydrogen, C 1 -C 4 - alkyl, Ci-C 4 -fluoroalkyl, Ci-C 4 -alkoxy and C 1 -C 4 - fluoroalkoxy,
• Z is a covalent bond or Ci-C 4 -alkandiyl
• R C1 which are bound at adjacent carbon atoms may form a fused 5- or 6-membered carbocyclic radical or a fused 5- or 6-membered heterocyclic radical having 1, 2 or 3 heteroatoms as ring members, which are selected from O, S and N;
• radicals R C1 which are bound at the same carbon atom may form a spiro 5- or 6-membered carbocyclic radical or a spiro 5- or 6-membered heterocyclic radical having 1 or 2 heteroatoms as ring members, which are selected from O, S and N,
• R C3 is a chemical bond, CH 2 , O, 0-CH 2 , S(0) 2 , NR y ', NR y, -CH 2 or NR y '-S(0) 2 , where R y ' is selected from the group consisting of hydrogen, Ci-C 4 -alkyl, Ci-C 4 -alkylcarbonyl, C 1 -C 4 - alkylsulfonyl, Ci-C 4 -fluoroalkylsulfonyl; is a carbocyclic or heterocyclic radical selected from the group consisting of phenyl, 3- to 7-membered saturated or partially unsaturated monocarbocyclic radicals, 3- to 7-membered saturated or partially unsaturated heteromonocyclic radicals, having 1 , 2 or 3 heteroatoms as ring members, which are selected from O, S and N, and 5-
• R C3 is selected from hydrogen, halogen, OH, CN, Ci-C4-alkyl, Ci- C4-alkoxy, hydroxy-Ci-C4-alkyl, Ci-C4-alkoxy-Ci-C4-alkyl, cyano-Ci-C4-alkyl, Ci-C4-fluoroalkyl, Ci-C4-fluoroalkoxy, C 2 - Ce-alkenyl, C(0)R a , benzyl, Z-C(0)OR b , Z-C(0)NR c R d , S(0) 2 NR c R d and Z-NR e R f , where, Z, R a , R b , R c , R d , R e and R f are as defined above or two radicals R C3 which are bound at the same atom may form an oxygen atom; provided that for X 3 being O or S, at least one of the radicals R 1 and R 7 is a
• R are a moiety Y -Cyc , Y -Cyc or Y -Cyc , respectively; and the N-oxides, the prodrugs, the tautomers and the hydrates thereof, and the pharmaceutically acceptable salts thereof.
• the present invention therefore relates to the compounds of the general formula I, their tautomers, the hydrates thereof, the pharmaceutically suitable salts of the compounds of formula I, the prodrugs of the compounds of formula I and the pharmaceutically suitable salts of said prodrugs, tautomers or hydrates of the
• the compounds of the formula I, their salts, their prodrugs, their hydrates and their tautomers effectively inhibit PDEIOA even at low concentrations. They are additionally distinguished by a high selectivity in relation to the inhibition of the
• the compounds of the invention may additionally have one or more of the properties ii. to viii. mentioned above.
• the compounds of the formula I, their salts, their prodrugs, their hydrates and their tautomers are therefore particularly suitable for treating disorders and conditions in creatures, especially human creatures, which can be treated or controlled by inhibition of phosphodiesterase type 10A.
• the invention therefore also relates to the use of carboxamide compounds of the formula I, their tautomers, their hydrates and their pharmaceutically suitable salts for the manufacture of a medicament, in particular of a medicament which is suitable for the treatment of a disorder or a condition which can be treated by inhibition of phosphodiesterase type 1 OA.
• the invention further relates to a medicament, in particular a medicament which is suitable for the treatment of a disorder or a condition which can be treated by inhibition of phosphodiesterase type 10A.
• the medicament comprises at least one compound of the formula I, as described herein, or a tautomer, or a hydrate or a prodrug of said compound I, or a pharmaceutically suitable salt of the compound of the formula I or a pharmaceutically suitable salt of the tautomer, the hydrate or the prodrug of compound of the formula I.
• prodrugs means compounds which are metabolized in vivo to the compounds I of the invention. Typical examples of prodrugs are described in C.G.
• Suitable prodrugs in the present case may be for example derivatives of those compounds I carrying an OH or NH 2 -group, where the OH or NH 2 -group forms an ester/amide/peptide linkage, i.e. where one of the hydrogen atoms of the OH or NH 2 -group is substituted by a Ci-C4-alkylcarbonyl group, e.g.
• an amino acid e.g. glycine, alanine, serine, phenylalanine and the like, which is linked to the oxygen or nitrogen of the OH or NH 2 -group via the carbonyl group of the amino acid.
• Such carbonates and carbamates are described for example in J. Alexander, R. Cargill, S. R. Michelson, H. Schwam, J. Medicinal Chem. 1988, 31(2), 318-322. These groups can then be eliminated under metabolic conditions and result in compounds I. Therefore, said prodrugs and their pharmaceutically acceptable salts are also part of the invention.
• pharmaceutically acceptable salts refers to cationic or anionic salts compounds, wherein the counter ion is derived from pharmaceutically acceptable nontoxic bases or acids including inorganic or organic bases and inorganic or organic acids.
• salts may be prepared from pharmaceutically acceptable non-toxic bases, including inorganic and organic bases.
• Salts derived from inorganic bases include salts, wherein the counter ion is aluminium, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc ion and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium ions.
• Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, dibenzylethylene-diamine, diethylamine, 2-diethylamino- ethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
• basic ion exchange resins such as argin
• salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
• acids include acetic, trifluoroacetic acid, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
• the compounds of the invention may be in the form of a mixture of
• the compounds are preferably in the form of essentially diastereomerically pure compounds (diastereomeric excess de > 90%).
• the compounds I of the invention may furthermore be in the form of a mixture of enantiomers (for example as racemate), of a mixture of enantiomers in which one of the two enantiomers is enriched, or essentially in enantiomerically pure compounds (enantiomeric excess ee > 90%). It is preferred to employ the compounds enantiomerically pure or diastereomerically pure.
• the present invention moreover relates to compounds as defined herein, wherein one or more of the atoms depicted in formula I have been replaced by its stable, preferably non-radioactive isotope (e.g., hydrogen by deuterium, 12 C by 13 C, 14 N by 15 N, 16 0 by 18 0) and preferably wherein at least one hydrogen atom has been replaced by a deuterium atom.
• the compounds according to the invention contain more of the respective isotope than this naturally occurs and thus is anyway present in the compounds I.
• the compounds of the formula I and their salts in the solid form may exist in more than one crystal structure (polymorphism), and may also be in the form of hydrates or other solvates.
• the present invention includes any polymorph of the compound I or its salt as well as any hydrate or other solvate.
• alkyl alkenyl, alkoxy, alkenyloxy, “fluoroalkyl”, “fluoroalkoxy”, “cycloalkyl”, “fluorinated cycloalkyl”, “alkylene”, “alkandiyl”, “hetaryl” and radicals derived therefrom, such as “alkylcarbonyl”, “alkylsulfanyl”, “alkylsulfonyl”,
• fluoroalkylsulfonyl "hydroxylalkyl", “cyanoalkyl", "alkoxylalkyl”, “alkoxy alkoxy”, “alkylsulfanylalkyl”, “alkylsulfanylalkoxy” and "hetarylmethyl” represent groups of individual radicals.
• C n -C m - indicates the respective number of carbons in the hydrocarbon unit. Unless indicated otherwise, fluorinated substituents preferably have one to five identical or different fluorine atoms.
• halogen designates in each case, fluorine, bromine, chlorine or iodine, specifically fluorine, chlorine or bromine.
• Fluoroalkyl and the fluoroalkyl moieties for example in fluoroalkylsulfonyl an alkyl radical having ordinarily 1 to 4 C atoms, in particular 1 or 2 C-atoms (d-C 2 - fluoroalkyl) as mentioned above, whose hydrogen atoms are partly or completely replaced by fluorine atoms such as fluoromethyl, difluoromethyl, trifluoromethyl, 2- fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2-fluoro-l- methylethyl, 2,2-difluoro-l -methylethyl, 2,2-trifluoro-l -methylethyl, 2-fluoropropyl, 3- fluoropropyl, 2,2-difluoropropyl, 2,3-difluoropropyl, 3,3,3-trifluoropropyl
• Fluorinated cycloalkyl monocyclic, saturated hydrocarbon groups having three or more C atoms, e.g. 3, 4, 5, 6 or 7 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, wherein at least one, e.g. 1 , 2, 3, 4, 5 or 6 of the hydrogen atoms are replaced by fluorine atoms, examples including 1- fluorocyclopropyl, 2-fluorocyclopropyl, 2,2-difluorocyclopropyl, 1 ,2- difluorocyclopropyl, 2,3-difluorocyclopropyl, etc..
• Cycloalkoxy a cycloalkyl radical as defined above which is linked via an oxygen atom, e.g. cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or cyclohexyloxy.
• Cycloalkylalkyl a cycloalkyl radical as defined above which is linked via an alkylene group, in particular via a methylene, 1 , 1 -ethylene or 1 ,2-ethylene group, e.g. cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl.
• an alkyl radical as defined above having preferably 1 to 4 C atoms, which is connected to the remainder of the molecule via an O atom: e.g. methoxy, ethoxy, n- propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1 , 1- dimethylethoxy.
• Fluoroalkoxy alkoxy as described above, in which the hydrogen atoms of these groups are partly or completely replaced by fluorine atoms, i.e. for example Ci-C 4 - fluoroalkoxy, in particular Ci-C 2 -fluoroalkoxy, such as fluoromethoxy,
• Hydroxyalkyl an alkyl radical ordinarily having 1 to 4 C atoms, in which one hydrogen atom is replaced by an OH radical. Examples thereof are CH 2 -OH, 1- hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 1 -methyl- 1- hydroxy ethyl, l-methyl-2-hydroxy ethyl, 3-hydroxypropyl, 2-hydroxybutyl, 3- hydroxybutyl, 4-hydroxybutyl, l-methyl-2-hydroxypropyl, l,l-dimethyl-2-hydroxyetyl,
• Cyanoalkyl an alkyl radical ordinarily having 1 to 4 C atoms, in which one hydrogen atom is replaced by a CN radical. Examples thereof are CH 2 -CN, 1- cyanoethyl, 2-cyanoethyl, 1-cyanopropyl, 2-cyanopropyl, 1 -methyl- 1-cyanoethyl, 1- methyl-2-cyanoethyl, 3-cyanopropyl, 2-cyanobutyl, 3-cyanobutyl, 4-cyanobutyl, 1- methyl-2-cyanopropyl, l,l-dimethyl-2-cyanoetyl, 1 -methyl- 1-cyanopropyl etc.
• Alkoxyalkyl an alkyl radical ordinarily having 1 to 4 C atoms, in which one hydrogen atom is replaced by an alkoxy radical ordinarily having 1 to 4 C atoms.
• Examples thereof are CH 2 -OCH 3 , CH 2 -OC 2 H 5 , n-propoxymethyl, CH 2 -OCH(CH 3 ) 2 , n-butoxymethyl, (l-methylpropoxy)methyl, (2-methylpropoxy)methyl, CH 2 -OC(CH 3 ) 3 ,
• Alkoxyalkoxy an alkoxyalkyl radical as defined above ordinarily having 1 to 4 C atoms both in the alkoxy and the alkyl moiety which is connected to the remainder of the molecule via an O atom: Examples thereof are OCH 2 -OCH 3 , OCH 2 -OC 2 H 5 , n- propoxymethoxy, OCH 2 -OCH(CH 3 ) 2 , n-butoxymethoxy, (l-methylpropoxy)methoxy, (2-methylpropoxy)methoxy, OCH 2 -OC(CH 3 )3, 2-(methoxy)ethoxy, 2-(ethoxy)ethoxy, 2-(n-propoxy)ethoxy, 2-( 1 -methylethoxy)ethoxy, 2-(n-butoxy)ethoxy,
• Alkylcarbonyl alkyl as defined above preferably having 1 to 4 C atoms, which is connected via a carbonyl group to the remainder of the molecule, e.g. acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl and the like.
• alkylsulfanylalkoxy alkyl as defined above preferably having 1 to 4 C atoms, which is connected via an S atom to the remainder of the molecule, e.g. methylsulfanyl, ethylsulfanyl, n-propylsulfanyl and the like.
• Alkylsulfonyl alkyl as defined above preferably having 1 to 4 C atoms, which is connected via an SO 2 group to the remainder of the molecule, e.g. methylsulfonyl, ethylsulfonyl, n-propylsulfonyl and the like.
• Fluoroalkylsulfanyl fluoroalkyl as defined above preferably having 1 to 4 C atoms, which is connected via an S atom to the remainder of the molecule, e.g.
• fluoromethylsulfanyl difluoromethylsulfanyl, trifluoromethylsulfanyl, 2- fluoroethylsulfanyl, 2,2-difluoroethylsulfanyl, 2,2,2-trifluoroethylsulfanyl,
• Fluoroalkylsulfonyl fluoroalkyl as defined above preferably having 1 to 4 C atoms, which is connected via an SO 2 group to the remainder of the molecule, e.g. fluoromethylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, 2- fluoroethylsulfonyl, 2,2-difluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl,
• Alkylsulfanylalkyl an alkyl radical ordinarily having 1 to 4 C atoms, in which one hydrogen atom is replaced by an alkylsulfanyl radical ordinarily having 1 to 4 C atoms. Examples thereof are CH 2 -SCH 3 , CH 2 -SC 2 H 5 , n-propylsulfanylmethyl,
• Alkylen or " Alkandiyl” : a saturated hydrocarbon chain having ordinarily from 1 to 4 carbon atoms, such as methylen (-CH 2 -), 1,2-ethylen (-CH 2 CH 2 -), 1,1-ethandiyl (-CH(CH 3 )-), 1 ,2-propandiyl, 1,3-propandiyl, 1 ,4-butandiyl, 1 ,2-butandiyl, 1,3- butandiyl, 1 -methyl- 1 ,2-propandiyl, 2-methyl- 1,3-propandiyl, 1 -methyl- 1,1-ethandiyl, 1 -methyl- 1 ,2-propandiyl etc.
• Saturated or partially unsaturated 4 to 7-membered monocarbocyclic radicals include cycloalkyl as defined above and cycloalkenyl having ordinarily from 4 to 7 carbon atoms as ring members, e.g. 1-cyclobuten-l-yl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2- cycloheptenyl, 3-cycloheptenyl.
• saturated heteromonocycles are in particular:
• Saturated heteromono cyclic radical which ordinarily has 3, 4, 5, 6 or 7 ring atoms, where ordinarily 1 , 2 or 3 of the ring atoms are heteroatoms such as N, S or O, besides carbon atoms as ring members.
• These include for example:
• N-bonded, 5-membered saturated rings such as: tetrahydropyrrol- 1 -yl, tetrahydropyrazol- 1 -yl, tetrahydroisoxazol-2-yl, tetrahydroisothiazol-2-yl, tetrahydroimidazol- 1 -yl, tetrahydrooxazol-3-yl, tetrahydrothiazol-3-yl.
• N-bonded, 6-membered saturated rings such as:
• Unsaturated heteromono cyclic radicals which ordinarily have 4, 5, 6 or 7 ring atoms, where ordinarily 1, 2 or 3 of the ring atoms are heteroatoms such as N, S or O, besides carbon atoms as ring members. These include for example:
• N-bonded, 5-membered, partially unsaturated rings such as:
• N-bonded, 6-membered, partially unsaturated rings such as:
• dihydroindolizynyl dihydroisoindolyl, dihydroquinolinyl, dihydroisoquinolinyl, chromenyl and chromanyl.
• Hetaryl a 5- or 6-membered aromatic heteromono cyclic radical (also termed 5- or 6-membered monocyclic hetaryl) which ordinarily has 1, 2, 3 or 4 heteroatoms as ring members, which are selected from O, S and N, and which has in particular 1, 2, 3 or 4 nitrogen atoms or a heteroatom selected from oxygen and sulfur and, if appropriate, 1 or 2 nitrogen atoms as ring members besides carbon atoms as ring members and a 8- to 10- membered aromatic heterobicyclic radical (also termed 8- to 10-membered bicyclic hetaryl) which ordinarily has 1 , 2, 3 or 4 heteroatoms as ring members, which are selected from O, S and N, and which has in particular 1, 2, 3 or 4 nitrogen atoms or a heteroatom selected from oxygen and sulfur and, if appropriate, 1 or 2 nitrogen atoms as ring members besides carbon atoms as ring members: for example
• pyridin-2-yl pyridin-3-yl, pyridin-4-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin- 2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, l,3,5-triazin-2-yl, 1,2,4-triazin-
• N-bonded, 5-membered heteroaromatic radicals having 1, 2, 3 or 4 nitrogen atoms as ring members such as:
• pyrrol- 1-yl pyrazol-l-yl, imidazol-l-yl, 1,2,3-triazol-l-yl, 1,2,4-triazol-l-yl, tetrazol-l-yl.
• 6- membered heterocycle fused thereto for example a fused benzene, thiophene, furane, pyrrole, pyrazole, imidazole, pyridine or pyrimidine ring.
• bicyclic hetaryl include for example quinolinyl, isoquinolinyl, cinnolinyl, indolyl, indolizynyl, isoindolyl, indazolyl, benzofuryl, benzothienyl, benzo[b]thiazolyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, imidazo[l,2-a]pyridine-2-yl, thieno[3,2-b]pyridine-5-yl, imidazo-[2,l-b]-thiazol-6-yl and l,2,4-triazolo[l,5- a]pyridine-2-yl.
• Hetarylalkyl a hetaryl radical as defined above which is linked via an alkylene group, in particular via a methylene, 1,1 -ethylene or 1,2-ethylene group, to the remainder of the molecule.
• the variables Het, A, A', Q, X 1 , X 2 , X 3 , Y 1 , Y 2 , Y 3 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , Cyc 1 , Cyc 2 and Cyc 3 preferably have the following meanings, where these represent, both considered on their own and in combination with at least one other or all, special configurations of the compounds of the formula I:
• Het is unsubstituted or may carry 1 , 2, 3 or 4 identical or different substituents R x .
• R x is selected from the group consisting of H, halogen, Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-fluoroalkyl, Ci-C4-fluoroalkoxy, C3-C6- cycloalkyl, Ci-C4-alkoxy-Ci-C4-alkoxy, Ci-C4-alkoxy-Ci-C4-alkyl, OH, hydroxy-Ci- C 4 -alkyl, 0-C 3 -C 6 -cycloalkyl, benzyloxy, C(0)0-(Ci-C 4 -alkyl), 0-(Ci-C 4 -alkyl)-C0 2 H, N(R xl )(R x2 ), C(0)N(R xl )(R x2 ).
• Het is preferably selected from the group consisting of C-bound 6-membered monocyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members, and C-bound, fused bicyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members and optionally a further heteroatom selected from O, S and N as ring member, where monocyclic hetaryl and bicyclic hetaryl may be unsubstituted or may carry 1 , 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 -fluoralkoxy, phenyl, C 3 - C6-cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C3-C6- cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy,
• Het is selected from fused bicyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members and optionally a further heteroatom selected from O, S and N as ring member and which may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, C 1 -C 4 - alkoxy, Ci-C 2 -fluoralkoxy, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• Het is selected from 6- membered monocyclic hetaryl, which may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, C 1 -C 2 - fluoralkoxy, phenyl, C3-C6-cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C3-C6-cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl or one R x may also be phenyl.
• Het radicals which have at least one imino- nitrogen as ring member, which is located in the position adjacent to the carbon atom which is bound to A.
• Het radicals which have at least one imino-nitrogen as ring member, which is located in the position adjacent to the carbon atom which is bound to tA and which are selected from the group consisting of C-bound 6-membered monocyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members, benzofuryl and C-bound, fused bicyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members and optionally a further heteroatom selected from O, S and N as ring member, where monocyclic hetaryl, benzofuryl and bicyclic hetaryl may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C 4 -alkyl, Ci-C 2 - fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoralkoxy, phenyl, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl,
• Het are selected from the group consisting of 2-benzofuryl,
• Het has at least one imino-nitrogen as ring member, which is located in the position adjacent to the carbon atom which is bound to A and Het is selected from the group consisting of fused bicyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members and optionally a further heteroatom selected from O, S and N as ring member, where bicyclic hetaryl may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, C 1 -C 4 - alkoxy, Ci-C 2 -fluoralkoxy, C3-C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C3-C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• Het of this embodiment are 2-quinolinyl, 3-isoquinolinyl, 2-quinazolinyl, 2-quinoxalinyl, 1,5- naphthyridin-2-yl, l,8-naphthyridin-2-yl, benzothiazol-l-yl, benzoxazol-l-yl, benzimidazol-2-yl, l-methylbenzimidazol-2-yl, imidazo[l,2-a]pyridine-2-yl, thieno[3,2- b]pyridine-5-yl, imidazo-[2,l-b]-thiazol-6-yl and l,2,4-triazolo[l,5-a]pyridine-2-yl, where the aforementioned radicals are unsubstituted or may carry 1 , 2 or 3 radicals R x as defined above, which are in particular selected from the group consisting of fluorine, chlorine, methyl, f uoromethyl
• variable X 1 is CH.
• X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• X 3 is preferably S or
• variable X 1 is N.
• X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• X 3 is preferably S or
• variable X 2 is C-R 7 .
• R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• X 1 is CH or preferably N.
• the variable X 2 is N.
• X 1 is preferably CH.
• X 3 is S.
• X 1 is CH or preferably N and X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• X 3 is O.
• X 1 is N or preferably CH
• X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 and R 1 is as defined above and in particular H or Y'-Cyc 1 .
• variable X 3 is
• X 1 is CH or preferably N and X 2 is preferably C- R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• X 1 is CH or preferably N and X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H and R 1 is as defined above and in particular Y'-Cyc 1 .
• R 9 is preferably H.
• X 1 is preferably CH and X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• R 7 is preferably H or Y 2 -
• R 9 is preferably H or Y 3 -Cyc 3 , while R 8 is preferably hydrogen.
• R 8 is preferably H.
• X 2 is C-R 7
• X 3 is
• R 7 is preferably H or Y 2 -Cyc 2
• R 9 is preferably H or Y 3 -Cyc 3
• R 8 is
• R 7 2 2 9 3 3 preferably hydrogen, where preferably either R is Y -Cyc or R is Y -Cyc while one
• radicals R 1 , R 7 and R 9 which are different from Y'-Cyc 1 , Y 2 -Cyc 2 , Y 3 -Cyc 3 , respectively, are in particular selected, independently of each other, from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, fluorinated Ci-C 2 -alkyl, Ci-C4-alkoxy, fluorinated Ci-C 2 -alkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• Those radicals R 1 , R 7 and R 9 which are
• Y -Cyc , Y -Cyc , Y -Cyc , respectively, are most preferably hydrogen.
• R 1 is Y'-Cyc 1 .
• X 1 is CH or preferably N and X 2 is preferably C-R 7 , where R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• R 7 is as defined above and in particular H or Y 2 -Cyc 2 .
• R 8 is preferably hydrogen.
• R 1 is different from
• Y'-Cyc 1 and in particular hydrogen.
• X 1 is CH or preferably N.
• X 2 is preferably C-R 7 , where R 7 is as defined above and in particular
• Y 1 is preferably selected from O, NH and a chemical bond. In particular Y 1 is a chemical bond.
• Y 2 is preferably selected from O, NH and a chemical bond.
• Y 2 is a chemical bond.
• Y 3 is preferably selected from O, NH and a chemical bond.
• Y 3 is a chemical bond.
• Cyc 1 is selected from the groups of
• phenyl or a 5- or 6 membered monocyclic hetaryl which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, 9- or 10-membered bicyclic hetaryl which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of indolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzimidazolyl, benzotriazolyl, benzopyrazolyl and benzo furyl, where phenyl and hetaryl are unsubstitute
• R 1 or 2 radicals R , where R , R" z and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• R C1 is preferably selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 , or, if Cyc 1 is phenyl, two radicals R C1 which are bound to adjacent carbon atoms, together with the phenyl ring to which they are bound, form a bicyclic heterocyclic radical, which is selected from 5- or 6-indolyl, 5- or 6-benzimidazolyl, 5- or 6-benzopyrazolyl, 5- or 6- benzotriazolyl, 5- or 6-benzofuranyl, 2,3-dihydrobenzofuran-5-yl, 2,3- dihydrobenzofuran-6-yl, l,3-dihydroindol-2-on-5-yl, l,3-dihydroindol-2-on-6-yl, 5- or 6-quinolinyl, 5- or 6-isoquinolinyl, 5- or 6-quin
• R C2 is preferably selected from the group consisting of phenyl, C 3 - C6-cycloalkyl, optionally substituted by 1, 2, or 3 methyl groups, fluorinated C 3 -C 6 - cycloalkyl, and 5- or 6-membered saturated heteromonocyclic radicals, having 1, 2 or 3 heteroatoms as ring members, which are selected from O, S and N, where phenyl the saturated heteromonocyclic radical is unsubstituted or carries 1, 2 or 3 radicals R C3 , which are preferably selected from fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 .
• Cyc 1 is selected from the groups of (i) saturated 4-, 5-, 6- or 7-membered heteromonocycles, where the
• phenyl or a 5- or 6 membered hetaryl selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y * -R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals
• R where R , R and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O.
• Y 1 is preferably selected from O, NH and a chemical bond, with particular preference given to Y 1 being a chemical bond.
• Y'-Cyc 1 is e.g. selected from the group consisting of 1-piperidinyl, 4,4-difluoro-l-piperidinyl, 4-piperidinyl, l-methyl-4- piperidinyl, 1-piperazinyl, 4-methyl-l-piperazinyl, morpholin-4-yl, 2-oxa-6-azaspiro- [3,4]octyl, 2,5-diazabicyclo[2.2. l]heptan-2-yl, 3,8-diazabicyclo[3.2.
• Cyc 1 is phenyl or a 5- or 6 membered heteroaromatic radical, which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered heteroaromatic radical are unsubstituted or either carry, independently of each other, carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y'-
• Cyc 1 is selected from the group consisting of phenyl or a 5- or 6 membered hetaryl, selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y * -R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals
• R where R , R" z and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O.
• Cyc 1 is selected from the group consisting of phenyl and 5- or 6- membered hetaryl selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and hetaryl are unsubstituted or carry 1, 2 or 3 radicals R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 , or, if Cyc 1 is phenyl, two radicals R C1 which are bound to adjacent carbon atoms, together with the phenyl ring to which they are bound, form a bicyclic heterocyclic radical, which is selected from 5- or 6-indolyl, 5- or 6-benzimidazolyl, 5- or 6-benzopyrazolyl, 5- or 6-benzotri
• Y 1 is a chemical bond.
• Cyc 1 is selected from the group consisting of phenyl and 5- or 6-membered hetaryl selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and hetaryl are unsubstituted or carry 1, 2 or 3 radicals R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and N3 ⁇ 4.
• Cyc 2 and Cyc 3 are, independently from each other, selected from the groups of
• R CI or one radi ⁇ cal Y * -R C"2 z and 0, 1, 2, 3 or 4, i ⁇ n particular 0, 1 or 2 radicals R CI , where R C1 , R C2 and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O; and
• phenyl or a 5- or 6 membered monocyclic hetaryl which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, 9- or 10-membered bicyclic hetaryl which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of indolyl, quinolinyl, isoquinolinyl, quinazolinyl, benzimidazolyl, benzotriazolyl, benzopyrazolyl and benzofuryl, where phenyl and hetaryl are unsubstit
• R 1 or 2 radicals R , where R , R" z and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• R C1 is preferably selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 , or, if Cyc 2 or Cyc 3 are phenyl, two radicals R C1 which are bound to adjacent carbon atoms, together with the phenyl ring to which they are bound, form a bicyclic heterocyclic radical, which is selected from 5- or 6-indolyl, 5- or 6-benzimidazolyl, 5- or 6-benzopyrazolyl, 5- or 6-benzotriazolyl, 5- or 6-benzofuranyl, 2,3-dihydrobenzofuran-5-yl, 2,3- dihydrobenzofuran-6-yl, l,3-dihydroindol-2-on-5-yl, l,3-dihydroindol-2-on-6-yl, 5- or 6-quinolinyl, 5- or 6-isoquinolinyl, 5- or 6-is
• R C2 is preferably selected from the group consisting of phenyl, C 3 - C 6 -cycloalkyl, optionally substituted by 1, 2, or 3 methyl groups, fluorinated C 3 -C 6 - cycloalkyl, and 5- or 6-membered saturated heteromonocyclic radicals, having 1, 2 or 3 heteroatoms as ring members, which are selected from O, S and N, where phenyl the saturated heteromonocyclic radical is unsubstituted or carries 1, 2 or 3 radicals R C3 , which are preferably selected from fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 .
• Cyc 2 and Cyc 3 are, independently from each other, selected from the groups of
• phenyl or a 5- or 6 membered hetaryl selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y'-R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals CI CI C2
• R where R , R and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O.
• R is preferably a chemical bond or O.
• R C1 2, or 3 radicals R C1 , where R C1 is as defined herein.
• Y 2 and Y 3 are, independently from each other preferably selected from O, NH and a chemical bond, with particular preference given to Y 2 and Y 3 being a chemical bond.
• Cyc 2 and Cyc 3 are, independently from each other, e.g. selected from the group consisting of 1-piperidinyl, 4,4-difluoro-l- piperidinyl, 4-piperidinyl, l-methyl-4-piperidinyl, 1-piperazinyl, 4-methyl-l- piperazinyl, morpholin-4-yl, 2-oxa-6-azaspiro-[3,4]octyl, 2,5- diazabicyclo[2.2. l]heptan-2-yl, 3,8-diazabicyclo[3.2.
• Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently of each other, phenyl or a 5- or 6 membered heteroaromatic radical, which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered heteroaromatic radical are unsubstituted or either carry, independently of each other, carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y * -R C2 and 0, 1, 2, 3 or 4, in particular 0,
• R 1 or 2 radicals R , where R , R" z and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently from each other, selected from the group consisting of phenyl or a 5- or 6 membered hetaryl, selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y'-R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals R C1 , where R C1 , R C2 and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• phenyl or a 5- or 6 membered hetaryl selected from pyridyl, pyrimidiny
• Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently from each other, selected from the group consisting of phenyl and 5- or 6-membered hetaryl selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and hetaryl are unsubstituted or carry 1 , 2 or 3 radicals R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 , or, if one or both of Y 2 - Cyc 2 and Y 3 -Cyc 3 are phenyl, two radicals R C1 which are bound to adjacent carbon atoms, together with the phenyl ring to which they are bound, form a bicyclic hetero
• Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently from each other, selected from the group consisting of phenyl and 5- or 6-membered hetaryl selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and hetaryl are
• R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 .
• R C1 is preferably selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 .
• R C2 is preferably selected from the group consisting of phenyl, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2, or 3 methyl groups, fluorinated C 3 -C 6 -cycloalkyl, and 5- or 6- membered saturated heteromonocyclic radicals, having 1 , 2 or 3 heteroatoms as ring members, which are selected from O, S and N, where phenyl the saturated
• heteromonocyclic radical is unsubstituted or carries 1, 2 or 3 radicals R C3 , which are preferably selected from fluorine, chlorine, CN, methyl, difluoromethyl,
• R 2 is preferably selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, C 1 -C 4 - alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• R 2 is in particular hydrogen.
• Q is in particular oxygen
• a in formula I is A 1 , A 2 , A 3 or A 4 .
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10 is a bivalent radical A 1 .
• R 5 and R 6 are, independently of each other, selected from the group consisting of hydrogen, fluorine and methyl, and in particular to those compounds, where both R 5 and R 6 are hydrogen.
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10, is a bivalent radical A 2 .
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10, is a bivalent radical A 3 .
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10, is a bivalent radical A 4 .
• R 3c are independently of each other selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 and where R 3b and R 3b are independently of each other in particular selected from the group consisting of hydrogen and fluorine.
• Particular preference is given to compounds of the formula I, and likewise to compounds of formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10, where A is a bivalent radical A 4 , where the moiety A' is CR 3b R 3c , where R 3b and R 3c are as defined herein and where R 3b and R 3c are in particular, independently of each other, selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 and especially where both R 3b and R 3c are hydrogen or fluorine.
• a in formula I and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10 is a bivalent radical A 4 , where A is O.
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10, is a bivalent radical A 4 , where A' is NR 3a with R 3a being as defined above in particular hydrogen or Ci-C 4 -alkyl.
• a in formula I is a bivalent radical A 4 , where A is linear C 2 - C 3 -alkanediyl, where one of the CH 2 -moieties of C 2 -C 3 -alkandiyl may be replaced by oxygen or NR 3a , and where 1, 2, 3, or 4 of the hydrogen atoms of C 2 -C 3 -alkandiyl may be replaced by a radical R 3d .
• R 3d is prefereably selected from halogen and Ci-C 4 -alkyl.
• a in formula I, and likewise in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9 and 1-10 is a bivalent radical A 5 .
• R 3e and R 3f are, independently of each other, selected from the group consisting of hydrogen and methyl, and in particular to those compounds, where both R 3e and R 3f are hydrogen.
• a particular preferred embodiment of the invention relates to the compounds of formula I-l .
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-2.
• A described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• Another particular preferred embodiment of the invention relates to the compounds of formula I-l .B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 5 and R 7 are as defined here and in the claims and where R 5 is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-2. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 5 and R 7 are as defined here and in the claims and where R 5 is in particular hydrogen.
• the variables R 3b and R 3c are independently of each other in particular selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 . Particular preference is given to compounds of the formulae I-l .B and 1-2. B, where both R 3b and R 3c are hydrogen or fluorine.
• Another particular preferred embodiment of the invention relates to the compounds of formula I-l .C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 and R 7 are as defined here and in the claims and where R is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-2. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 and R 7 are as defined here and in the claims and where R is in particular hydrogen.
• a particular preferred embodiment of the invention relates to the compounds of formula I-l .D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f and R 7 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-2. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f and R 7 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Particular embodiments of the invention relate to compounds of the formulae 1-1 , 1-2, 1-l .A, I-2.A, I-l .B, I-2.B, I-l .C, I-2.C, I-l .D, and I-2.D described above, to the N- oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof, where R 1 is a radical Y'-Cyc 1 and R 7 is as defined above and in particular selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 - fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups, fluorinated cyclopropyl and Y 2 -Cyc 2 , especially from the group consisting of hydrogen and Y 2 -Cyc 2 .
• R 1 is selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 - fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups and fluorinated cyclopropyl and R 7 is a moiety Y 2 -Cyc 2 .
• R 1 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-3.A, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined here and in the claims.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-4.
• A described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined here and in the claims.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-3. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 7 , R 8 and R 9 are as defined here and in the claims and where R 5 is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-4. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 7 , R 8 and R 9 are as defined here and in the claims and where R 5 is in particular hydrogen.
• R 3b and R 3c are independently of each other in particular selected from the group consisting of hydrogen, fluorine and methyl or together form CH2CH2. Particular preference is given to compounds of the formulae 1-3. B and I-4.B, where both R 3b and R 3c are hydrogen or fluorine.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-3. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-4. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f , R 7 , R 8 and R 9 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-4. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f , R 7 , R 8 and R 9 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Particular embodiments of the invention relate to compounds of the formulae 1-3, 1-4, 1-3.A, 1-4.A, 1-3. B, I-4.B, 1-3. C, 1-3.D, I-4.C, and I-4.D, described above, to the N- oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof, where R 1 is a radical Y'-Cyc 1 and R 7 , R 8 and R 9 are as defined above and where R 7 is in particular selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoroalkoxy,
• cyclopropyl optionally substituted by 1 , 2 or 3 methyl groups, fluorinated cyclopropyl and Y 2 -Cyc 2 , especially from the group consisting of hydrogen and Y 2 -Cyc 2 and where R 9 is in particular selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups, fluorinated cyclopropyl and Y 3 -Cyc 3 , especially from the group consisting of hydrogen and Y 3 -Cyc 3 , provided that none or only one of 7 9 3 3 3 3 7 9
• R and R is a moiety Y -Cyc , or Y -Cyc , respectively.
• R and R are in particular hydrogen.
• R 1 is selected from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C2-fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 - fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups and fluorinated cyclopropyl and where R 7 and R 9 are selected, independently of each other, from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, C1-C4- alkoxy, Ci-C 2 -fluor
• R is Y -Cyc or R is Y -Cyc .
• R is in particular hydrogen.
• the radical R 7 or R 9 which is different from Y 2 -Cyc 2 or Y 3 -Cyc 3 , respectively, is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-5.A, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 6 , R 7 and R 8 are as defined here and in the claims.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-6.
• A described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 6 , R 7 and R 8 are as defined here and in the claims.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-5.
• B described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 5 , R 7 and R 8 are as defined here and in the claims and where R 5 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-6. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3a , R 3b , R 5 , R 7 and R 8 are as defined here and in the claims and where R 5 is in particular hydrogen.
• the variables R 3b and R 3c are independently of each other in particular selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 .
• Particular preference is given to compounds of the formulae 1-5.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-5. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 5 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-6. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 5 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-5. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R , R e , R , R , R and R are as defined here and in the claims and in particular, R 3e and R 3f are both hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-6. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f , R 7 , R 8 and R 9 are as defined here and in the claims and in particular, R 3e and R 3f are both hydrogen.
• Particular embodiments of the invention relate to compounds of the formulae 1-5, 1-6, 1-5.A, I-6.A, 1-5. B, I-6.B, 1-5. C, I-6.C, 1-5.D and I-6.D, described above, to the N- oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof, where R 1 is a radical Y'-Cyc 1 and R 7 is as defined above and in particular selected from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C 2 - fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups, fluorinated cyclopropyl and Y 2 -Cyc 2 , especially from the group consisting of hydrogen and Y 2 -Cyc 2 .
• R 1 is selected from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 - fluoroalkoxy, cyclopropyl, optionally substituted by 1 , 2 or 3 methyl groups and fluorinated cyclopropyl and R 7 is a moiety Y 2 -Cyc 2 .
• R 1 is in particular hydrogen.
• a particular preferred embodiment of the invention relates to the compounds of formula I-7.A, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-8.
• A described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-7. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 5 and R 7 are as defined here and in the claims and where R 5 is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-8. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 5 and R 7 are as defined here and in the claims and where R 5 is in particular hydrogen.
• R 3b and R 3c are independently of each other in particular selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 . Particular preference is given to compounds of the formulae I-7.B and I-8.B, where both R 3b and R 3c are hydrogen or fluorine.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-7. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 and R 7 are as defined here and in the claims and where R is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-8. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 and R 7 are as defined here and in the claims and where R is in particular hydrogen.
• a particular preferred embodiment of the invention relates to the compounds of formula 1-7. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3f , R 3e and R 7 are as defined here and in the claims where R 3e and R are both in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-8. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3f , R 3e and R 7 are as defined here and in the claims where R 3e and R are both in particular hydrogen.
• Particular embodiments of the invention relate to compounds of the formulae 1-7, 1-8, 1-7.A, I-8.A, I-7.B, I-8.B, I-7.C, I-8.C, I-7.D, and I-8.D described above, to the N- oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof, where R 1 is a radical Y'-Cyc 1 and R 7 is as defined above and in particular selected from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C 2 - fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, fluorinated cyclopropyl and Y 2 -Cyc 2 , especially from the group consisting of hydrogen and Y 2 -Cyc 2 .
• R 1 is selected from the group consisting of hydrogen, fluorine, Ci-C4-alkyl, Ci-C2-fluoroalkyl, Ci-C4-alkoxy, C1-C2- fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups and fluorinated cyclopropyl and R 7 is a moiety Y 2 -Cyc 2 .
• R 1 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-9.
• R 1 , R 2 , R 5 , R 6 , R 7 and R 9 are as defined here and in the claims.
• Another particular preferred embodiment of the invention relates to the compounds of formula I-10.A, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 6 , R 7 , and R 9 are as defined here and in the claims.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-9. B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• Another particular preferred embodiment of the invention relates to the compounds of formula I-10.B, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3b , R 3c , R 7 , and R 9 are as defined here and in the claims and where R 5 is in particular hydrogen.
• R 3b and R 3c are independently of each other in particular selected from the group consisting of hydrogen, fluorine and methyl or together form CH 2 CH 2 . Particular preference is given to compounds of the formulae 1-3.B and I-4.B, where both R 3b and R 3c are hydrogen or fluorine.
• Another particular preferred embodiment of the invention relates to the compounds of formula 1-9. C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 7 , and R 9 are as defined here and in the claims and where R 5 is in particular hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula I-10.C, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 5 , R 7 , and R 9 are as defined here and in the claims and where R 5 is in particular hydrogen.
• a further particular preferred embodiment of the invention relates to the compounds of formula 1-9. D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f , R 7 , and R 9 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Another particular preferred embodiment of the invention relates to the compounds of formula I-10.D, described below, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof:
• R 1 , R 2 , R 3e , R 3f , R 7 , and R 9 are as defined here and in the claims and where R 3e and R 3f are in particular both hydrogen.
• Particular embodiments of the invention relate to compounds of the formulae 1-9, I- 10, 1-9.A, I-10.A, I-9.B, I-10.B, I-9.C, I-10.C, I-9.D and I-10.D, described above, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the pharmaceutically suitable salts thereof, where R 1 is a radical Y'-Cyc 1 and R 7 , and R 9 are as defined above and where R 7 is in particular selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, fluorinated cyclopropyl and Y 2 -Cyc 2 , especially from the group consisting of hydrogen and Y 2 -Cyc 2 and where R 9 is
• R and R is a moiety Y -Cyc , or Y -Cyc , respectively.
• R and R are in particular hydrogen.
• R 1 is selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, C 1 -C 2 - fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups and fluorinated cyclopropyl and where R 7 and R 9 are selected, independently of each other, from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, C 1 -C 4 - alkoxy, Ci-
• R is Y -Cyc or R is Y -Cyc .
• R is in particular hydrogen.
• the radical R 7 or R 9 which is different from Y 2 -Cyc 2 or Y 3 -Cyc 3 , respectively, is in particular hydrogen.
• R 2 is preferably selected from the group consisting of hydrogen, fluorine, Ci-C 4 -alkyl, C 1 -C 2 - fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 -fluoroalkoxy, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• R 2 is in particular hydrogen.
• R 3b , R 3c , R 5 and R 6 are, independently of each other, selected from the group consisting of hydrogen, fluorine and methyl, and in particular to those compounds, where both R 5 and R 6 are hydrogen.
• R x is preferably selected from halogen, Ci-C 4 -alkyl, Ci-C 2 -fluoroalkyl, Ci-C 4 -alkoxy, Ci-C 2 - fluoralkoxy, phenyl, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, phenyl, cyclopropyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated cyclopropyl.
• R x is preferably selected from halogen, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 - fluoralkoxy, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy,
• Het is selected from 6-membered monocyclic hetaryl, which may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C4-alkyl, Ci-C 2 - fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 -fluoralkoxy, phenyl, C3-C6-cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C3-C6-cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl,
• the Het radical has at least one imino-nitrogen as ring member, which is located in the position adjacent to carbon atom bound to the group CR 5 and which is selected from the group consisting of C-bound 6-membered monocyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members, and C-bound, fused bicyclic hetaryl, which has 1 or 2 nitrogen atoms as ring members and optionally a further heteroatom selected from O, S and N as ring member, where monocyclic hetaryl and bicyclic hetaryl may be unsubstituted or may carry 1, 2, 3 or 4 substituents R x , in particular 0, 1 or 2 substituents R x .
• R x is preferably selected from halogen, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 -fluoralkoxy, phenyl, C 3 - C6-cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 - cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy,
• radicals are unsubstituted or may carry 1, 2 or 3 radicals Rx as defined above, which are in particular selected from the group consisting of fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy,
• R x is preferably selected from halogen, Ci-C4-alkyl, Ci-C 2 -fluoroalkyl, Ci-C4-alkoxy, Ci-C 2 - fluoralkoxy, C 3 -C 6 -cycloalkyl, optionally substituted by 1, 2 or 3 methyl groups, and fluorinated C 3 -C 6 -cycloalkyl.
• R x is in particular selected from fluorine, chlorine, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy,
• Het of this embodiment are 2-quinolinyl, 3-isoquinolinyl, 2-quinazolinyl, 2-quinoxalinyl, 1,5- naphthyridin-2-yl, l,8-naphthyridin-2-yl, benzothiazol-l-yl, benzoxazol-l-yl, benzimidazol-2-yl, l-methylbenzimidazol-2-yl, imidazo[l,2-a]pyridine-2-yl, thieno[3,2- b]pyridine-5-yl, imidazo-[2,l-b]-thiazol-6-yl and l,2,4-triazolo[l,5-a]pyridine-2-yl, where the aforementioned radicals
• I-10.D is selected from the group consisting of 2- quinolinyl, l,8-naphthyridin-2-yl, benzothiazol-l-yl, benzoxazol-l-yl, benzimidazol-2- yl, l-methylbenzimidazol-2-yl, imidazo[l,2-a]pyridine-2-yl, thieno[3,2-b]pyridine-5-yl, and in particular 2-quinolinyl or imidazo[l,2-a]pyridine-2-yl, where these radicals are unsubstituted or may carry 1 , 2 or 3 radicals R
• Cyc 1 if present in formulae 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1- 10, 1-1.A, I-l .B, I-2.A, I-2.B, I-l .C, I-2.C, I-l .D, I-2.D, 1-3.A, 1-4.A, 1-3.B, I-4.B, I-3.C, I-4.C, I-3.D, I-4.D, I-5.A, I-6.A, I-5.B, I-6.B, I-5.C, I-6.C, I-5.D, I-6.D, I-7.A, I-8.A, I- 7.B, I-8.B, I-7.C, I-8.C, I-7.D, I-8.D, I-9.A, I-10.A, I-9.B, I-10.B, I-9.C, I-IO.C, I-9.D and I- 10 D is selected from the groups of
• phenyl or a 5- or 6 membered hetaryl selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y * -R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals
• R where R , R and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O.
• if present, is e.g. selected from the group consisting of 1-piperidinyl, 4,4-difluoro-l-piperidinyl, 4-piperidinyl, 1- methyl-4-piperidinyl, 1-piperazinyl, 4-methyl-l-piperazinyl, morpholin-4-yl, 2-oxa-6- azaspiro-[3,4]octyl, 2,5-diazabicyclo[2.2. l]heptan-2-yl, 3,8-diazabicyclo[3.2.
• Cyc 1 if present, is phenyl or a 5- or 6 membered heteroaromatic radical, which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered heteroaromatic radical are unsubstituted or either carry, independently of each other, carry 1, 2, 3, 4 or
• R is preferably a chemical bond or O.
• Cyc 1 if present, is selected from the group consisting of phenyl or a 5- or 6 membered hetaryl, selected from pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered hetaryl are unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3
• Cyc 1 if present in formulae 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1- 9, 1-10, 1-l .A, I-l .B, I-2.A, I-2.B, I-l .C, I-2.C, I-l .D, I-2.D, 1-3.A, 1-4.A, 1-3.B, I-4.B, I- 3.C, I-4.C, I-3.D, I-4.D, I-5.A, I-6.A, I-5.B, I-6.B, I-5.C, I-6.C, I-5.D, I-6.D, I-7.A, I- 8.A, I-7.B, I-8.B, I-7.C, I-8.C, I-7.D, I-8.D, I-9.A, I-10.A, I-9.B, I-10.B, I-9.C, I-10.C, I- 9.D and I-10.D, is selected from the group
• R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and NH 2 .
• Cyc 2 and Cyc 3 if present in formulae I-l, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1- 8, 1-9, 1-10, I-l . A, I-l .B, I-2.A, I-2.B, I-l .C, I-2.C, I-l .D, I-2.D, 1-3.A, 1-4.A, 1-3.B, I- 4.B, I-3.C, I-4.C, I-3.D, I-4.D, I-5.A, I-6.A, I-5.B, I-6.B, I-5.C, I-6.C, I-5.D, I-6.D, I- 7.A, I-8.A, I-7.B, I-8.B, I-7.C, I-8.C, I-7.D, I-8.D, I-9.A, I-10.A, I-9.B, I-10.B, I-9.C, I- 10.C, I-9.D and I-10.D
• R where R , R" z and Y * are as defined herein and where Y', if present, is preferably a chemical bond or O.
• R in particular 0, 1 or 2 radicals R , where R , R and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• I-10.B, I-9.C, I-10.C, I-9.D and I-10.D, Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently from each other, e.g. selected from the group consisting of 1-piperidinyl, 4,4-difluoro-l-piperidinyl, 4-piperidinyl, l-methyl-4-piperidinyl, 1-piperazinyl, 4- methyl- 1-piperazinyl, morpholin-4-yl, 2-oxa-6-azaspiro-[3,4]octyl, 2,5- diazabicyclo[2.2.
• phenyl or a 5- or 6 membered heteroaromatic radical which has one heteroatom, selected from O, S and N as ring member and optionally one or two further heteroatoms as ring members, and which is in particular selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and the 5- or 6 membered heteroaromatic radical are unsubstituted or either carry, independently of each other, carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y * -R C2 and 0, 1, 2, 3 or 4, in particular 0,
• R 1 or 2 radicals R , where R , R" z and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• R C1 unsubstituted or carry 1, 2, 3, 4 or 5, in particular 1, 2, or 3 radicals R C1 or one radical Y'-R C2 and 0, 1, 2, 3 or 4, in particular 0, 1 or 2 radicals R C1 , where R C1 , R C2 and Y' are as defined herein and where Y', if present, is preferably a chemical bond or O.
• Y 2 -Cyc 2 and Y 3 -Cyc 3 if present in formulae 1-1, 1-2, 1-3, 1-4, 1-5, 1-
• R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy
• Y -Cyc and Y -Cyc are phenyl, two radicals R which are bound to adjacent carbon atoms, together with the phenyl ring to which they are bound, form a bicyclic heterocyclic radical, which is selected from 5- or 6-indolyl, 5- or 6-benzimidazolyl, 5- or 6-benzopyrazolyl, 5- or 6-benzotriazolyl, 5- or 6-benzofuranyl, 2,3-dihydrobenzofuran-5-yl, 2,3-dihydrobenzofuran-6-yl, 1 ,3-dihydroindol-2-on-5-yl, l,3-dihydroindol-2-on-6-yl, 5- or 6-quinolinyl, 5- or 6-isoquinolinyl, 5- or 6- quinazolinyl, 2-amino-5-quinazolinyl, and 2-a
• Y 2 -Cyc 2 and Y 3 -Cyc 3 are, independently from each other, selected from the group consisting of phenyl and 5- or 6-membered hetaryl selected from the group consisting of pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl and thiazolyl, where phenyl and hetaryl are unsubstituted or carry 1, 2 or 3 radicals R C1 which are selected from the group consisting of fluorine, chlorine, CN, methyl, difluoromethyl, trifluoromethyl, methoxy and N3 ⁇ 4.
• Particular embodiment of the invention relates to the compounds of formula I, to the N-oxides, the prodrugs, the hydrates and the tautomers thereof and to the
• Het, A, X 1 , R 2 , R 6 and R 8 are as defined for formulae I, I-l .A, I-l .B, I-2.A, I-2.B,
• R 1 a , R 7a , R 9a independently of each other, are selected from the group
• Ci-C4-alkyl consisting of hydrogen, halogen, Ci-C4-alkyl, trimethylsilyl, C1-C4- alkylsulfanyl, Ci-C4-alkoxy-Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-alkoxy- Ci-C4-alkoxy, Ci-C4-alkylsulfanyl-Ci-C4-alkoxy, C2-C4-alkenyloxy, Ci-C 4 -fluoroalkyl, Ci-C 4 -fluoroalkoxy, CN, NR xl R x2 , NR xl R x2 -Ci-C 4 - alkoxy;
• radicals R la , R 7a and R 9a in particular exactly one of these radicals is bromine or iodine, while the others are different from bromine or iodine;
• M is a Li, B(OR B1 )(OR B2 ) radical or an Sn(R Sn ) 3 radical, where R B1 and R B2 are, independently of each other, hydrogen or Ci-C4-alkyl or R B1 and R B2 together form a C 2 -C6-alkandiyl moietyl, e.g. ethan-l,2-diyl, propan-l,3-diyl or l,l ,2,2-tetramethylethan-l,2-diyl, and wherein R Sn is Ci-C6-alkyl or C3- C6-cycloalkyl or phenyl.
• Y is a chemical bond
• R B1 and R B2 are hydrogen, the trimers thereof.
• reaction of the compound II with the compound III can be performed by analogy to known coupling reactions in the presence of suitable transition metal catalysts, in particular palladium catalysts.
• suitable transition metal catalysts in particular palladium catalysts.
• Typical reactions conditions are those of Stille coupling (see e.g. Stille et al. Angew. Chem. Int. Ed. Engl. 1986, 25,508;
• compounds of the formula I where Y 1 , Y 2 or Y 3 is NH or were Cyc'-Y 1 , Cyc 2 -Y 2 or Cyc 3 -Y 3 (Y 1 , Y 2 or Y 3 are single bonds) an N-bound heterocycle (Y 1 , Y 2 or Y 3 are single bonds) can be prepared by reacting a compound of the formula II, as defined above, with a compound of the formula III'
• reaction of II with III' is preferably carried out in an aprotic solvent, such as dimethylsulfoxide, acetonitrile, N- methylpyrrolidone, dimethylformamide, dimethylacetamide, tetramethyl urea, or mixtures thereof or mixtures thereof with halogenated hydrocarbons such as
• the reaction is preferably carried out in the presence of a suitable base, e.g. an alkalimetal carbonate such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate or an alkalimetal alkoxide.
• a suitable base e.g. an alkalimetal carbonate such as lithium carbonate, sodium carbonate, potassium carbonate or caesium carbonate or an alkalimetal alkoxide.
• X 2b is N or C-R 7b ;
• Het, A, X 1 , R 2 and R 8 are as defined for formulae I, I- LA, I- LB, 1-2. A, I-2.B, I- l .C, I-2.C, I-l .D, I-2.D, 1-3.A, 1-4.A, 1-3.B, I-4.B, I-3.C, I-4.C, 1-3.D,
• I-4.D I-5.A, I-6.A, I-5.B, I-6.B, I-5.C, I-6.C, I-5.D, I-6.D, I-7.A, I-8.A, I-7.B, I-8.B, I-7.C, I-8.C, I-7.D, I-8.D, I-9.A, I-10.A,I-9.B, I-10.B, I- 9.C, I-10.C, I-9.D or I-10.D;
• R lb , R 7b , R 9b independently of each other, are selected from the group
• Ci-C4-alkyl consisting of hydrogen, Ci-C4-alkyl, trimethylsilyl, C1-C4- alkylsulfanyl, Ci-C4-alkoxy-Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-alkoxy- Ci-C4-alkoxy, Ci-C4-alkylsulfanyl-Ci-C4-alkoxy, C2-C4-alkenyloxy, Ci-C 4 -fluoroalkyl, Ci-C 4 -fluoroalkoxy, CN, NR xl R x2 , NR xl R x2 -Ci-C 4 - alkoxy or a moiety M;
• Hal-Y-Cyc (Illb) where Y and Cyc are as defined herein and wherein Hal is bromine or iodine.
• reaction of the compound Ila with the compound Illb can be performed by analogy tot the reaction of compound II with compound III.
• the compounds II, Ila, III, III', Ilia and Illb are known or can be prepared by standard methods of organic chemistry.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Hospice & Palliative Care (AREA)
• Child & Adolescent Psychology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Psychology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47178004

Family Applications (1)

Country Status (26)

Cited By (12)

Families Citing this family (23)

Citations (52)

Family Cites Families (5)

• 2012
  • 2012-10-25 US US13/660,524 patent/US20130116241A1/en not_active Abandoned
  • 2012-10-29 US US13/663,008 patent/US9273068B2/en not_active Expired - Fee Related
  • 2012-11-08 CA CA2852604A patent/CA2852604A1/en not_active Abandoned
  • 2012-11-08 AU AU2012334074A patent/AU2012334074A1/en not_active Abandoned
  • 2012-11-08 PE PE2014000642A patent/PE20141938A1/es not_active Application Discontinuation
  • 2012-11-08 RU RU2014123316/04A patent/RU2014123316A/ru not_active Application Discontinuation
  • 2012-11-08 WO PCT/EP2012/072150 patent/WO2013068470A1/en not_active Ceased
  • 2012-11-08 SG SG11201402142VA patent/SG11201402142VA/en unknown
  • 2012-11-08 AR ARP120104208A patent/AR088801A1/es unknown
  • 2012-11-08 KR KR1020147015427A patent/KR20140097318A/ko not_active Withdrawn
  • 2012-11-08 EP EP12784578.2A patent/EP2776418B1/en not_active Not-in-force
  • 2012-11-08 CN CN201280052929.8A patent/CN104053654A/zh active Pending
  • 2012-11-08 HK HK15101856.4A patent/HK1201519A1/xx unknown
  • 2012-11-08 JP JP2014540459A patent/JP2014534976A/ja active Pending
  • 2012-11-08 ES ES12784578T patent/ES2620531T3/es active Active
  • 2012-11-08 BR BR112014011284A patent/BR112014011284A2/pt not_active IP Right Cessation
  • 2012-11-08 MX MX2014005714A patent/MX2014005714A/es unknown
  • 2012-11-08 PH PH1/2014/500877A patent/PH12014500877A1/en unknown
  • 2012-11-09 TW TW101141932A patent/TW201326153A/zh unknown
  • 2012-11-09 UY UY0001034445A patent/UY34445A/es not_active Application Discontinuation
• 2014
  • 2014-04-23 ZA ZA2014/02966A patent/ZA201402966B/en unknown
  • 2014-04-29 IL IL232358A patent/IL232358A0/en unknown
  • 2014-05-07 GT GT201400089A patent/GT201400089A/es unknown
  • 2014-05-08 DO DO2014000097A patent/DOP2014000097A/es unknown
  • 2014-05-08 CL CL2014001212A patent/CL2014001212A1/es unknown
  • 2014-05-14 CR CR20140223A patent/CR20140223A/es unknown
  • 2014-06-04 CO CO14119455A patent/CO7030959A2/es unknown
• 2016
  • 2016-01-18 US US14/997,997 patent/US9657034B2/en not_active Expired - Fee Related

Patent Citations (53)

Non-Patent Citations (59)

Also Published As

Similar Documents

Legal Events